Wavelet Medical Partners with Aegis Ventures to Advance AI Fetal Brain Monitoring

Wavelet Medical has partnered with Aegis Ventures to commercialize an AI-powered fetal brain monitoring platform, announced in a press release. The collaboration includes $7 million in seed funding to bring Wavelet’s non-invasive fetal electroencephalography (EEG) technology from laboratory research to global clinical use.

Developed at Yale, the system uses EEG signals captured through the mother's abdomen and reconstructed with proprietary AI algorithms to detect fetal brain distress in real time. This approach differs from traditional fetal heart rate monitoring by directly measuring neurological activity, aiming to prevent brain injury at birth and reduce unnecessary caesarean sections.

Wavelet’s technology is currently being tested at three clinical sites, including those affiliated with USC and LA General. The company plans to expand trials as it moves toward commercialization. Aegis Ventures, which co-founds healthtech startups with academic and healthcare partners, will support product development, clinical adoption, and global rollout.